Table 1.
Demographics and Outcomes of COVID-19 Patients with Myasthenia Gravis.
| Cohort characteristics | |
|---|---|
| No. of MG patients with COVID-19 | 380 (out of 40,460)a |
| Demographics | |
| Age, mean (SD), years | 63.2 ± 16.4 |
| Women, n (%) | 185 (48.7%) |
| Men, n (%) | 195 (51.3%) |
| Race | |
| White Caucasian | 241 (63%) |
| African American | 62 (16%) |
| Unknown race | 68 (18%) |
| Ethnicity | |
| Not Hispanic or Latino | 243 (64%) |
| Hispanic or Latino | 36 (9%) |
| Unknown Ethnicity | 101 (27%) |
| Outcome | |
| Hospitalization | 102 (26.8%) |
| ICU requirement | 38 (10%) |
| Intubation | 20 (5.3%) |
| Death | 26 (6.8%) |
| MG Crisis/Exacerbationb | 20 (5.3%) |
| Odds ratio (95% CI) of clinical outcome in MG with COVID-19 | ||
|---|---|---|
| Compared to entire COVID-19 cohort without MG (n = 370,009)c | Compared to age/gender matched COVID-19 cohort without MG (n = 380)d | |
| Hospitalization | 3 (2.4–3.8) | 1.7 (1.2–2.5) |
| ICU requirement | 5.2 (3.7–7.3) | 2.9 (1.5–5.5) |
| Intubation | 4.6 (2.9–7.3) | 1.7 (0.8–3.5) |
| Death | 4.3 (2.9–6.4) | 2 (1.1–3.9) |
Myasthenia Gravis (MG); Intensive Care Unit (ICU); Confidence Interval (CI).
a
Infection rate of 0.93% in the MG cohort.
b
MG crisis/exacerbation was captured based on ICD code (see appendix for details).
c
A total of 370,009 non-MG COVID-19 patients were identified in the database (out of 61,344,077).
d
An age and gender matched non-MG cohort was identified by propensity score matching as a comparison group.